Abstract
Over the last approximately 20 years, the pharmaceutical industry has increasingly outsourced its research and development activities, including pharmacovigilance, with mixed results. To avoid significant failures, both clients and service providers should understand and openly discuss each other’s needs, avoiding the unrealistic expectations often elicited prior to signing a contract. Clients should ensure the outsourced project is adequately resourced in terms of time allocated to it and the skills and expertise of those who will do the actual work and training. They should recognise that quality can be compromised by cheapness and that a service provider’s physical distance and cultural difference are likely to interfere with communication and reciprocal understanding. Clients should always have a person in house who has a good knowledge of pharmacovigilance, so as to understand each activity in detail. This person should be involved in discussions with the service provider, assessing the support and information that the service provider requires, reviewing the vendor’s work, providing continuous feedback and avoiding confrontation by focussing on the needs and challenges the service provider is facing.
Similar content being viewed by others
References
Getz K, Lamberti MJ, Kaitin KI. Taking the pulse of strategic outsourcing relationships. Clin Ther. 2014;36(10):1349–55.
Research and Markets. Global pharmacovigilance market analysis and forecast, 2015–2022. BIS Res. September 2016.
Edwards B, Wylie G. Outsourcing pharmacovigilance: perspectives of a global CRO, Chapter 7. In: Parexel International Corporation. Pharmacovigilance: effective safety surveillance strategies. Scrip reports 2002. London: PJB Publication Ltd. p. 217–55.
Henderson L. The state of CRO and sponsor relationships. Appl Clin Trials. 2013;10:26–8.
Hughes J, Rayer E, Wadd K. Sponsor-CRO Collaboration Study. Boston: Vantage Partners LLC; 2013.
Heads of Medicines Agency, European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I: pharmacovigilance systems and their quality systems. EMA/541760/2011; 2012.
European Medicines Agency. Pharmacovigilance inspection policy for centralised procedures: medicinal products for human use. EMA/INS/PhV/163771/2013 Rev 1; 2013.
Heads of Medicines Agency, European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module III: pharmacovigilance inspections. EMA/119871/2012 Rev 1; 2014.
van Leeuwen BP, Prendergast C, Edwards B, et al. Can pharmacovigilance learn from the oil and gas industry, which has been outsourcing for over a century? Ther Innov Regul Sci. 2017;51(1):11–5.
Kieran Trevett. GPvP inspections of contract service providers, August 2016 update. MHRA Inspectorate blog. https://mhrainspectorate.blog.gov.uk/2016/08/23/gpvp-inspections-of-contract-service-providers-august-2016-update/. Accessed 10 Jan 2017.
Good Pharmacovigilance Practice Inspectorate, Medicines and Healthcare Products Regulatory Agency. Pharmacovigilance Inspection Metrics Report, April 2015–March 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/550781/Pharmacovigilance_Inspection_Metrics_Report_2015-2016_FINAL.pdf. Accessed 10 Jan 2017.
Edwards B. How should you safely outsource pharmacovigilance to an Indian CRO? Indian J Pharmacol. 2008;40(Suppl. 1):S25–7.
Acknowledgements
The authors thank Mr. David Power, Helsinn Birex Pharmaceuticals, for reviewing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for the preparation of this article.
Conflict of interest
Giovanni Furlan and Bert van Leeuwen are employees of a pharmaceutical company. Brian Edwards is an employee of a company providing pharmacovigilance services to pharmaceutical companies.
Rights and permissions
About this article
Cite this article
Furlan, G., van Leeuwen, B. & Edwards, B. Considerations for Good Pharmacovigilance Outsourcing Practices. Pharm Med 31, 75–80 (2017). https://doi.org/10.1007/s40290-017-0183-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40290-017-0183-9